Influence of mutations in epidermal growth factor receptor gene on growth, metastasis and survival rate of non-small cell lung carcinoma

National Medical Journal of China

Volumn 90, Issue 26, 2010, Pages 1808-1812

  Yin, Xiao Wen ^a   Jiang, Xing Tang ^a   Yuan, Ya Ting ^a   Du, Yan Ping ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Carcinoma, non small cell lung; Mutation; Neoplasm metastasis; Receptor, epidermal growth factor; Survival rate

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; ADULT; AGED; CANCER STAGING; FEMALE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84871414681     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.26.004     Document Type: Article

References (22)

1. Molina J R, Yang P, Cassivi S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83: 584-594.
2. Gonfiotti A, Crocetti E, Lopes Pegna A, et al. Prognostic variability in completely resected pNl non-small-cell lung cancer. Asian Cardiovasc Thorac Ann, 2008, 16: 375-380.
3. Koike T, Tsuchiya R, Goya T, et al. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol, 2007, 2: 408-413.
4. Hubbard S R. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell, 2005, 7: 287-288.
5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 2006, 12: 5268-5272.
6. Kaneko K, Kumekawa Y, Makino R, et al. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci, 2010, 15:65-72.
7. Kosaka T, Yatabe Y, Onozato R. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol, 2009, 4:22-29.
8. 2006, 10: 1001-1003.
9. 2006, 33: 253-255.
10. Lynch T J, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129-2139.
11. Paze J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304: 1497-1500.
12. Qin B M, Chen X, Zhu J D, et al. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res, 2005, 15: 212-217.
13. 2008, 16:553-556.
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 2004, 101: 13306-13311.
15. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with posto- perative recurrence. J Clin Oncol, 2005, 23: 2513-2520.
16. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004, 64: 8919-8923.
17. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97: 339-346.
18. Zhang G C, Lin J Y, Wang Z, et al. Epidermal growth factor receptor double activating mutations involving both exon19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol, 2007, 19: 499-506.
19. Zhu J Q, Zhong W Z, Zhang G C, et al. Better survival with EGFR exon 19 than 21 mutations in gefitinib- treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters, 2008, 265: 307-317.
20. Sordella R, Bell D W, Haber D A, et al. Gefitinib-sensitizing EGFR in lung cancer active anti-apoptotic pathways. Science, 2004, 305: 1163-1167.
21. Ryan A J, Wedge S R. ZD6474-a novel inhibitor of VEGFR and EGFR trosine kinase activity. Br J Cancer, 2005, 92: S6-S13.
22. Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res, 2005, 11: 4521-4532.